103 related articles for article (PubMed ID: 11238879)
1. Repair of a Rev-minus human immunodeficiency virus type 1 mutant by activation of a cryptic splice site.
Verhoef K; Bilodeau PS; van Wamel JL; Kjems J; Stoltzfus CM; Berkhout B
J Virol; 2001 Apr; 75(7):3495-500. PubMed ID: 11238879
[TBL] [Abstract][Full Text] [Related]
2. Splicing regulatory elements within tat exon 2 of human immunodeficiency virus type 1 (HIV-1) are characteristic of group M but not group O HIV-1 strains.
Bilodeau PS; Domsic JK; Stoltzfus CM
J Virol; 1999 Dec; 73(12):9764-72. PubMed ID: 10559286
[TBL] [Abstract][Full Text] [Related]
3. A naturally arising mutation of a potential silencer of exon splicing in human immunodeficiency virus type 1 induces dominant aberrant splicing and arrests virus production.
Wentz MP; Moore BE; Cloyd MW; Berget SM; Donehower LA
J Virol; 1997 Nov; 71(11):8542-51. PubMed ID: 9343212
[TBL] [Abstract][Full Text] [Related]
4. Activation of a cryptic splice donor in human immunodeficiency virus type-1.
Borg KT; Favaro JP; Arrigo SJ; Schmidt M
J Biomed Sci; 1999 Jan; 6(1):45-52. PubMed ID: 9933742
[TBL] [Abstract][Full Text] [Related]
5. Biological importance and cooperativity of HIV-1 regulatory gene splice acceptors.
Riggs NL; Little SJ; Richman DD; Guatelli JC
Virology; 1994 Jul; 202(1):264-71. PubMed ID: 8009838
[TBL] [Abstract][Full Text] [Related]
6. The Effect of a Single Nucleotide Substitution in the Splicing Silencer in the tat/rev Intron on HIV Type 1 Envelope Expression.
Paca-Uccaralertkun S; Damgaard CK; Auewarakul P; Thitithanyanont A; Suphaphiphat P; Essex M; Kjems J; Lee TH
AIDS Res Hum Retroviruses; 2006 Jan; 22(1):76-82. PubMed ID: 16438649
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins.
Ulich C; Harrich D; Estes P; Gaynor RB
J Virol; 1996 Jul; 70(7):4871-6. PubMed ID: 8676525
[TBL] [Abstract][Full Text] [Related]
8. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
Liem SE; Ramezani A; Li X; Joshi S
Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
[TBL] [Abstract][Full Text] [Related]
9. Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1.
Staffa A; Cochrane A
Mol Cell Biol; 1995 Aug; 15(8):4597-605. PubMed ID: 7623851
[TBL] [Abstract][Full Text] [Related]
10. Efficiency of reinitiation of translation on human immunodeficiency virus type 1 mRNAs is determined by the length of the upstream open reading frame and by intercistronic distance.
Luukkonen BG; Tan W; Schwartz S
J Virol; 1995 Jul; 69(7):4086-94. PubMed ID: 7769666
[TBL] [Abstract][Full Text] [Related]
11. Evidence for CTL-mediated selection of Tat and Rev mutants after the onset of the asymptomatic period during HIV type 1 infection.
Guillon C; Stankovic K; Ataman-Onal Y; Biron F; Verrier B
AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1283-92. PubMed ID: 17209772
[TBL] [Abstract][Full Text] [Related]
12. Regulation of HIV-1 envelope protein synthesis by Tat and Rev in 293 cells.
Natarajan V; Radjendirane V; Salzman NP
Virology; 1993 Sep; 196(1):122-9. PubMed ID: 8356789
[TBL] [Abstract][Full Text] [Related]
13. The tat/rev intron of human immunodeficiency virus type 1 is inefficiently spliced because of suboptimal signals in the 3' splice site.
Staffa A; Cochrane A
J Virol; 1994 May; 68(5):3071-9. PubMed ID: 7512159
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
15. Modulation of HTLV-I gene expression by HIV-1 Rev through an alternative RxRE-independent pathway mediated by the RU5 portion of the 5'-LTR.
Kubota S; Furuta RA; Hatanaka M; Pomerantz RJ
Biochem Biophys Res Commun; 1998 Feb; 243(1):79-85. PubMed ID: 9473483
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV-1 replication by targeting the Rev protein.
Nakaya T; Iwai S; Fujinaga K; Otsuka E; Ikuta K
Leukemia; 1997 Apr; 11 Suppl 3():134-7. PubMed ID: 9209321
[TBL] [Abstract][Full Text] [Related]
17. The tat gene and protein of the human immunodeficiency virus type 1.
Caputo A; Grossi MP; Rossi C; Campioni D; Balboni PG; Corallini A; Barbanti-Brodano G
New Microbiol; 1995 Jan; 18(1):87-110. PubMed ID: 7760763
[No Abstract] [Full Text] [Related]
18. The strength of the HIV-1 3' splice sites affects Rev function.
Kammler S; Otte M; Hauber I; Kjems J; Hauber J; Schaal H
Retrovirology; 2006 Dec; 3():89. PubMed ID: 17144911
[TBL] [Abstract][Full Text] [Related]
19. Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics.
Ragheb JA; Bressler P; Daucher M; Chiang L; Chuah MK; VandenDriessche T; Morgan RA
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1343-53. PubMed ID: 8573391
[TBL] [Abstract][Full Text] [Related]
20. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference.
Coburn GA; Cullen BR
J Virol; 2002 Sep; 76(18):9225-31. PubMed ID: 12186906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
